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another article reporting that GcMAF successfully treated 
HIV, again determining success with Nagalase [4]. In 
the cancer-related articles, the authors claim Nagalase is 
exclusively produced by cancer cells as opposed to the 
HIV-related article where they claim Nagalase is a viral 
component.
The authors do not give the most basic information 
on the disease of these patients: No TNM, no stage, 
no histology. They determined that these patients had 
metastatic disease, based exclusively on an elevated 
level of serum Nagalase. Nagalase is not a criterion 
to define metastatic disease in the TNM classification 
of cancer [5]. No key opinion leader has validated its 
use in oncology.
The claim “Although their serum Nagalase activities 
indicated that they have significant amounts of metasta-
sized tumor cells, CT did not detect metastasized tumor 
lesions in other organs” means these patients did not have 
residual disease before starting GcMAF. All evidence cited 
to justify Nagalase use in this trial is publications by the 
same group (33 references that are cited 155 times against 
the 18 times the remaining 15 references are).
We have found the following about Yamamoto’s work:
1. The Nagasaki and the Hyogo Immunotherapy Research 
Groups, that gave IRB approval for these trials, do not 
exist except in Yamamoto’s clinical papers. Three pur-
ported members of these groups, including one chair-
man, informed us they are not part of these groups 
and that they have never been involved in Yamamoto’s 
activities. Other members of these IRBs could not be 
found.
2. Yamamoto’s co-authors in these papers could not be 
found.
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Dear Editors,
After several patients asked our organization, the Antican-
cer Fund, www.anticancerfund.org, about GcMAF as a 
cancer treatment, we looked for the evidence supporting its 
use in cancer. The literature showed us striking issues and 
inconsistencies. We would like to comment on the article 
from Yamamoto et al. published in your journal in 2008 [1].
It is claimed that eight colorectal cancer patients were 
successfully treated with GcMAF, a protein claimed to 
be discovered by the authors. “Treatment success” was 
determined by Nagalase in serum. Nagalase is supposed 
to deglycosilate naturally occurring GcMAF in cancer 
patients so that it is incapable of activating macrophages to 
fight cancer. GcMAF manufactured by Yamamoto might be 
unaffected by Nagalase.
This article was published in parallel to two other 
articles by the same group in other journals, claiming 
that their product (GcMAF) successfully treated pros-
tate [2] and breast cancer [3]. In 2009, they published 
This comment refers to the article available at doi:10.1007/
s00262-007-0431-z.
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3. We contacted the sponsors of these trials (US Public 
Health Service and the Elsa U. Pardee Foundation), 
and we found that they did not support them. They 
only supported Yamamoto’s early preclinical work 
while he was affiliated to other institutions rather than 
his Socrates Institute for Therapeutic Immunology.
This article also contains many mistakes and uses inva-
lid endpoints:
1. Many references are used inappropriately and most 
do not support the authors’ claims. For example: The 
assertion “Administration of 100 nanogram (ng) 
GcMAF to humans results in the maximal activation 
of macrophages with 30-fold increased ingestion index 
and 15-fold increased superoxide-generating capacity” 
has no basis. This statement is supported by reference 
33, which is an animal experiment in which these num-
bers are not mentioned. Furthermore, it has been dem-
onstrated that naturally occurring GcMAF in cancer 
patients has a concentration of approximately 4 mg/L, 
making the 100 ng proposed by Yamamoto meaning-
less, plus it is not deglycosilated [6].
2. Without adequate randomized controlled clinical trials, 
the assertion “Since the molecular structure of GcMAF 
is identical to that of the native human MAF, GcMAF 
(even 5-fold higher therapeutic dosage) produced no 
side effects” is wrong and dangerous. It is well estab-
lished that injection of some human products (i.e., 
insulin and epinephrine) into patients can be lethal.
3. The conclusions make no sense: “The curative rate 
measurements of tumors during GcMAF therapy and 
the estimation of the degree of tumor differentiation 
have been possible because of the availability of pre-
cision measurement of serum Nagalase”. Yamamoto 
proved that Nagalase failed as a disease measure-
ment method when it was compared to CT scans at 
the beginning of the study. However, at the end of the 
study, when the CT scans matched the authors’ specu-
lations, CT scans were again reported. The degree of 
tumor differentiation can only be determined by histo-
pathology, which was not reported in this or their other 
articles (prostate and breast cancer articles).
These results cannot be scientifically validated as they 
contradict established tenets in oncology.
Acknowledgments The Anticancer Fund is a private non-for-profit 
organization that provides to patients and their families evidence-
based information on different cancer therapies. This organization 
also supports the development of cancer therapies unlikely to be prof-
itable but that have shown promising results for cancer patients. For 
more information please visit our website www.anticancerfund.org.
Conflict of interest The authors declare no conflicts of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Yamamoto N, Suyama H, Nakazato H, Koga Y (2008) Immuno-
therapy of metastatic colorectal cancer with vitamin D-binding 
protein-derived macrophage-activating factor, GcMAF. Cancer 
Immunol Immunother 57:1007–1016
 2. Yamamoto N, Suyama H, Yamamoto N (2008) Immunother-
apy for prostate cancer with Gc protein-derived. Transl Oncol 
1:65–72
 3. Yamamoto N, Suyama H, Ushijima N (2008) Immunotherapy of 
metastatic breast cancer patients with vitamin D-binding protein-
derived macrophage activating factor (GcMAF). Int J Cancer 
122:461–467
 4. Yamamoto N, Ushijima N, Koga Y (2009) Immunotherapy of 
HIV-infected patients with Gc protein-derived macrophage acti-
vating factor (GcMAF). J Med Virol 81:16–26
 5. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM clas-
sification of malignant tumors. Wiley, New Jersey
 6. Rehder DS, Nelson RW, Borges CR (2009) Glycosylation sta-
tus of vitamin D binding protein in cancer patients. Protein Sci 
18:2036–2042
